SEC Filings

10-Q
ARRAY BIOPHARMA INC filed this Form 10-Q on 05/10/2017
Entire Document
 

NOTE 3 – COLLABORATION AND OTHER AGREEMENTS
The following table summarizes total revenue recognized for the periods indicated (in thousands):
 
 
Three Months Ended
 
Nine Months Ended
 
 
March 31,
 
March 31,
 
 
2017
 
2016
 
2017
 
2016
Reimbursement revenue
 
 
 
 
 
 
 
 
Novartis (1)
 
$
26,085

 
$
36,941

 
$
85,354

 
$
73,912

 
 
 
 
 
 
 
 
 
Collaboration and other revenue
 
 
 
 
 
 
 
Loxo
 
1,937

 
2,568

 
6,742

 
8,287

Pierre Fabre
 
1,919

 

 
6,072

 

Mirati
 
875

 
900

 
2,625

 
2,474

Novartis (2)
 
450

 
900

 
1,350

 
2,700

Asahi Kasei
 
257

 

 
885

 

Cascadian Therapeutics
 
71

 
63

 
123

 
107

Biogen Idec
 

 

 

 
2,816

Celgene
 

 
782

 

 
2,224

Other partners
 
21

 
36

 
52

 
192

Total collaboration and other revenue
5,530

 
5,249

 
17,849

 
18,800

 
 
 
 
 
 
 
 
 
License and milestone revenue
 
 
 
 
 
 
 
 
Pierre Fabre
 
750

 
750

 
2,250

 
855

Asahi Kasei
 
600

 

 
1,800

 

Mirati
 
209

 

 
625

 

Loxo
 
106

 
107

 
6,571

 
1,107

Roche
 

 

 
2,500

 

Other Partners
 

 

 
125

 

Total license and milestone revenue
 
1,665

 
857

 
13,871

 
1,962

Total revenue
 
$
33,280

 
$
43,047

 
$
117,074

 
$
94,674

                                       
 
 
 
 
 
 
 
 

(1) Consists of reimbursable expenses incurred and accrued as reimbursement revenue that are receivable under the Transition Agreements with Novartis.
(2)
Represents the recognition of revenue that was deferred from the consideration received in March 2015 upon the effective date of the Termination and Asset Transfer Agreement with Novartis relating to binimetinib.

Deferred revenue balances were as follows for the dates indicated (in thousands):
 
March 31,
 
June 30,
 
2017
 
2016
Pierre Fabre
$
26,145

 
$
28,395

Asahi Kasei
9,600

 
11,400

Mirati
2,542

 
3,167

Loxo
2,798

 
4,049

Novartis
450

 
1,800

Other partners
4

 
6

Total deferred revenue
41,539

 
48,817

Less: Current portion
(10,360
)
 
(12,856
)
Deferred revenue, long-term portion
$
31,179

 
$
35,961



14